ArrestinDb

Ligand source activities (1 row/activity)

Potency
Affinity

Get vendors

Ligands (move mouse cursor over ligand name to see structure)					Receptor			Assay information							Chemical information
Sel. page	Common name	GPCRdb ID	#Vendors	Reference ligand	Fold selectivity	# Tested GPCRs	Species	p-value (-log)	Activity Type	Activity Relation	Activity Value	AssayType	Assay Description	Source	Mol weight	Rot Bonds	H don	H acc	LogP	Smiles	DOI
	CHEMBL3102930	211038	0	None	-	1	Human	10.3	pEC50	=	10.3	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@]1(C)CCCC/C=C\CCCC[C@](C)(NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	168299476	192746	0	None	-1	3	Human	10.2	pEC50	=	10.2	Functional	Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4660	165	74	67	-19.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C(C)C)C(C)C)C(C)C)[C@@H](C)O	10.1021/acs.jmedchem.0c01396
	CHEMBL5220770	192746	0	None	-1	3	Human	10.2	pEC50	=	10.2	Functional	Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4660	165	74	67	-19.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C(C)C)C(C)C)C(C)C)[C@@H](C)O	10.1021/acs.jmedchem.0c01396
	CHEMBL4294827	213532	0	None	2	2	Human	10.1	pEC50	=	10.1	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H]1CNC[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)NC(CC(N)=O)CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O	nan
	CHEMBL1893324	209060	24	None	-1	3	Human	10.1	pEC50	=	10.1	Functional	Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(N)=O	10.1021/acs.jmedchem.0c01396
	2263	257	0	None	-1	3	Human	10.1	pEC50	=	10.1	Functional	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		None	10.1021/jm0609059
	44566111	257	0	None	-1	3	Human	10.1	pEC50	=	10.1	Functional	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		None	10.1021/jm0609059
	CHEMBL219499	257	0	None	-1	3	Human	10.1	pEC50	=	10.1	Functional	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		None	10.1021/jm0609059
	CHEMBL3102924	211032	0	None	-	1	Human	10.0	pEC50	=	10	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL3102925	211033	0	None	-	1	Human	10.0	pEC50	=	10.0	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CCC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(C)C	10.1021/ml400257h
	CHEMBL3102919	211027	0	None	-	1	Human	9.9	pEC50	=	9.9	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL4277441	213371	0	None	1202	2	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	1152	3995	16	None	-3	8	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	16129679	3995	16	None	-3	8	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	53395115	3995	16	None	-3	8	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	91898389	3995	16	None	-3	8	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL1981592	3995	16	None	-3	8	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL3102922	211030	0	None	-	1	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL3102929	211037	0	None	-	1	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL3102931	211039	0	None	-	1	Human	9.5	pEC50	=	9.5	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@]1(C)CCCC/C=C\CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL3102921	211029	0	None	-	1	Human	9.4	pEC50	=	9.4	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL3105020	211071	0	None	-	1	Human	9.4	pEC50	=	9.4	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@]1(C)CCCC/C=C\CCCC[C@@](C)(C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC1=O)C(C)C	10.1021/ml400257h
	CHEMBL4291119	213506	0	None	22	2	Human	9.4	pEC50	=	9.4	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(CCCCN)CC(=O)NCC(=O)NCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4277799	213380	0	None	977	2	Human	9.3	pEC50	=	9.3	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4285873	213459	0	None	-	1	Human	9.2	pEC50	=	9.2	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL440082	213860	0	None	-	1	Human	9.2	pEC50	=	9.2	Functional	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)O	10.1021/jm0609059
	CHEMBL4282016	213428	0	None	204	2	Human	9.2	pEC50	=	9.2	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O	nan
	CHEMBL4281547	213421	0	None	-	1	Human	9.1	pEC50	=	9.1	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4277870	213381	0	None	1659	2	Human	9.1	pEC50	=	9.1	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4294951	213534	0	None	-	1	Human	9.0	pEC50	=	9.0	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4289726	213487	0	None	-	1	Human	9.0	pEC50	=	9.0	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)NC(CC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)NCCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)Cc1ccc(O)cc1)[C@@H](C)O	nan
	CHEMBL3102923	211031	0	None	-	1	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL4291903	213511	0	None	660	2	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)NC(CC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(CC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)Cc1ccc(O)cc1)[C@@H](C)O	nan
	CHEMBL4276843	213367	0	None	-	1	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(CC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4286419	213463	0	None	234	2	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4282364	213431	0	None	1071	2	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NC(CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL3102926	211034	0	None	-	1	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C	10.1021/ml400257h
	CHEMBL4283432	213440	0	None	-	1	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCNC(=N)N)CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL3102927	211035	0	None	-	1	Human	8.8	pEC50	=	8.8	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@](C)(CCCC=C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C	10.1021/ml400257h
	CHEMBL3105019	211070	0	None	-	1	Human	8.8	pEC50	=	8.8	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@]1(C)CCCC/C=C\CCCC[C@@](C)(C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(C)C	10.1021/ml400257h
	CHEMBL4294843	213533	0	None	-11	2	Human	7.0	pEC50	=	7.0	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)NC(CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4281814	213424	0	None	-58	2	Human	6.6	pEC50	=	6.6	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4284858	213449	0	None	-	1	Human	8.5	pEC50	=	8.5	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4287451	213469	0	None	426	2	Human	8.5	pEC50	=	8.5	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)NC(CCC(N)=O)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL3102928	211036	0	None	-	1	Human	8.4	pEC50	=	8.4	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@](C)(CCCC=C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC	10.1021/ml400257h
	CHEMBL4280273	213405	0	None	-	1	Human	6.5	pEC50	=	6.5	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4277709	213377	0	None	-870	2	Human	5.3	pEC50	=	5.3	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4278228	213388	0	None	-	1	Human	8.3	pEC50	=	8.3	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O	nan
	CHEMBL4281905	213426	0	None	1	2	Human	7.3	pEC50	=	7.3	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4285866	213458	0	None	-	1	Human	6.3	pEC50	=	6.3	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)CC(CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL3102920	211028	0	None	-	1	Human	8.2	pEC50	=	8.2	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL4277783	213379	0	None	1	2	Human	6.2	pEC50	=	6.2	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)CC(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CC(CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4284839	213448	0	None	-11	2	Human	6.1	pEC50	=	6.1	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)CC(CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4280734	213409	0	None	-223	2	Human	7.1	pEC50	=	7.1	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4284961	213451	0	None	9	2	Human	7.0	pEC50	=	7.0	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(C)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1CNC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)CC(Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O	nan
	CHEMBL4278811	213392	0	None	-	1	Human	6.0	pEC50	=	6	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	11570626	2550	46	None	-794	8	Human	4.9	pIC50	=	4.9	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	9135	2550	46	None	-794	8	Human	4.9	pIC50	=	4.9	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	CHEMBL1933349	2550	46	None	-794	8	Human	4.9	pIC50	=	4.9	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	DB12044	2550	46	None	-794	8	Human	4.9	pIC50	=	4.9	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	60170971	81401	0	None	-186	3	Human	5.8	pIC50	=	5.8	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4ccc(Cl)c(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	CHEMBL2159348	81401	0	None	-186	3	Human	5.8	pIC50	=	5.8	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4ccc(Cl)c(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	60170970	81400	0	None	-281	4	Human	5.6	pIC50	=	5.6	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4cc(Cl)ccc4Cl)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	CHEMBL2159347	81400	0	None	-281	4	Human	5.6	pIC50	=	5.6	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4cc(Cl)ccc4Cl)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	60171059	81402	0	None	-794	4	Human	5.6	pIC50	=	5.6	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	621	9	2	5	7.9	COc1ccc2cc(-c3cc(-c4cc(Cl)cc(C(F)(F)F)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	CHEMBL2159349	81402	0	None	-794	4	Human	5.6	pIC50	=	5.6	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	621	9	2	5	7.9	COc1ccc2cc(-c3cc(-c4cc(Cl)cc(C(F)(F)F)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	90154832	153119	0	None	-	1	Human	5.4	pIC50	=	5.4	Functional	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	CHEMBL3976408	153119	0	None	-	1	Human	5.4	pIC50	=	5.4	Functional	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	168298339	192709	0	None	-1	3	Human	8.4	pIC50	=	8.4	Functional	Antagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAntagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4137	147	67	59	-16.2	CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](CCS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C	10.1021/acs.jmedchem.0c01396
	CHEMBL5219662	192709	0	None	-1	3	Human	8.4	pIC50	=	8.4	Functional	Antagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAntagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4137	147	67	59	-16.2	CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](CCS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C	10.1021/acs.jmedchem.0c01396
	1152	3995	16	None	-3	8	Human	7.3	pEC50	=	7.3	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	16129679	3995	16	None	-3	8	Human	7.3	pEC50	=	7.3	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	53395115	3995	16	None	-3	8	Human	7.3	pEC50	=	7.3	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	91898389	3995	16	None	-3	8	Human	7.3	pEC50	=	7.3	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	CHEMBL1981592	3995	16	None	-3	8	Human	7.3	pEC50	=	7.3	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	16133238	2990	0	None	-85	6	Human	7.6	pEC50	=	7.6	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2257	2990	0	None	-85	6	Human	7.6	pEC50	=	7.6	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	44134520	2990	0	None	-85	6	Human	7.6	pEC50	=	7.6	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2258	2991	0	None	-17	4	Human	7.7	pEC50	=	7.7	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	1152	3995	16	None	-3	8	Human	7.8	pEC50	=	7.8	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	16129679	3995	16	None	-3	8	Human	7.8	pEC50	=	7.8	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	53395115	3995	16	None	-3	8	Human	7.8	pEC50	=	7.8	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	91898389	3995	16	None	-3	8	Human	7.8	pEC50	=	7.8	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	CHEMBL1981592	3995	16	None	-3	8	Human	7.8	pEC50	=	7.8	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	2272	3078	0	None	14	3	Human	8.3	pEC50	=	8.3	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2259	3346	0	None	190	4	Human	8.3	pEC50	=	8.3	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	1152	3995	16	None	-3	8	Human	9.2	pEC50	=	9.2	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	16129679	3995	16	None	-3	8	Human	9.2	pEC50	=	9.2	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	53395115	3995	16	None	-3	8	Human	9.2	pEC50	=	9.2	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	91898389	3995	16	None	-3	8	Human	9.2	pEC50	=	9.2	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	CHEMBL1981592	3995	16	None	-3	8	Human	9.2	pEC50	=	9.2	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2258	2991	0	None	-17	4	Human	9.3	pEC50	=	9.3	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	129887154	583	0	None	177	3	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	155817438	583	0	None	177	3	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16214732	583	0	None	177	3	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2269	583	0	None	177	3	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2281	583	0	None	177	3	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16133238	2990	0	None	-85	6	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2257	2990	0	None	-85	6	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	44134520	2990	0	None	-85	6	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2272	3078	0	None	14	3	Human	8.4	pEC50	=	8.4	Functional	inhibition of calcium influx stimulated by 30nM VIP in CHO cells stably expressing recombinant receptorinhibition of calcium influx stimulated by 30nM VIP in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2278	328	0	None	-4168	3	Human	5.9	pEC50	=	5.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	1152	3995	16	None	-3	8	Human	7.9	pEC50	=	7.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	16129679	3995	16	None	-3	8	Human	7.9	pEC50	=	7.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	53395115	3995	16	None	-3	8	Human	7.9	pEC50	=	7.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	91898389	3995	16	None	-3	8	Human	7.9	pEC50	=	7.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	CHEMBL1981592	3995	16	None	-3	8	Human	7.9	pEC50	=	7.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	16133238	2990	0	None	-85	6	Human	8.4	pEC50	=	8.4	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2257	2990	0	None	-85	6	Human	8.4	pEC50	=	8.4	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	44134520	2990	0	None	-85	6	Human	8.4	pEC50	=	8.4	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2276	3345	0	None	316	2	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	1152	3995	16	None	-3	8	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	16129679	3995	16	None	-3	8	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	53395115	3995	16	None	-3	8	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	91898389	3995	16	None	-3	8	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	CHEMBL1981592	3995	16	None	-3	8	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2259	3346	0	None	190	4	Human	8.7	pEC50	=	8.7	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	1152	3995	16	None	-3	8	Human	9.3	pEC50	=	9.3	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	16129679	3995	16	None	-3	8	Human	9.3	pEC50	=	9.3	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	53395115	3995	16	None	-3	8	Human	9.3	pEC50	=	9.3	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	91898389	3995	16	None	-3	8	Human	9.3	pEC50	=	9.3	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	CHEMBL1981592	3995	16	None	-3	8	Human	9.3	pEC50	=	9.3	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	2278	328	0	None	-4168	3	Human	5.0	pEC50	>	5	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2278	328	0	None	-4168	3	Human	5.0	pEC50	>	5	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	3842	2436	0	None	-1584	5	Human	6.0	pEC50	>	6	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2272	3078	0	None	14	3	Human	7.6	pIC50	=	7.6	Functional	inhibition of cyclic AMP formation stimulated by 0.3nM VIP in CHO cells stably expressing recombinant receptorinhibition of cyclic AMP formation stimulated by 0.3nM VIP in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633

Get vendors

Ligands (move mouse cursor over ligand name to see structure)					Receptor			Assay information							Chemical information
Sel. page	Similar- ity	Common name	GPCRdb ID	#Vendors	Reference ligand	Fold selectivity	# Tested GPCRs	Species	p-value (-log)	Activity Type	Activity Relation	Activity Value	Assay Type	Assay Description	Source	Mol weight	Rot Bonds	H don	H acc	LogP	Smiles	DOI
		CHEMBL524852	215621	6	None	-	0	Human	8.0	pIC50	=	8.0	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
		118334911	144316	0	None	-	0	Human	5.0	pIC50	=	5	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	534	10	4	5	2.8	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)CCC2	nan
		CHEMBL3905363	144316	0	None	-	0	Human	5.0	pIC50	=	5	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	534	10	4	5	2.8	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)CCC2	nan
		73890927	148895	0	None	-	0	Human	6.0	pIC50	=	6.0	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	524	11	4	6	2.4	COc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		CHEMBL3941654	148895	0	None	-	0	Human	6.0	pIC50	=	6.0	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	524	11	4	6	2.4	COc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		118334840	148530	0	None	-	0	Human	6.0	pIC50	=	6.0	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	11	4	5	2.9	CCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		CHEMBL3938565	148530	0	None	-	0	Human	6.0	pIC50	=	6.0	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	11	4	5	2.9	CCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		118334843	149252	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	508	10	4	5	2.7	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		CHEMBL3944350	149252	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	508	10	4	5	2.7	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		2263	257	0	None	-	1	Human	7.9	pIC50	=	7.9	Binding	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		None	10.1021/jm0609059
		44566111	257	0	None	-	1	Human	7.9	pIC50	=	7.9	Binding	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		None	10.1021/jm0609059
		CHEMBL219499	257	0	None	-	1	Human	7.9	pIC50	=	7.9	Binding	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		None	10.1021/jm0609059
		90154832	153119	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
		CHEMBL3976408	153119	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
		118334841	153521	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	519	10	4	6	2.2	N#Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		CHEMBL3979900	153521	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	519	10	4	6	2.2	N#Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		118334918	148852	0	None	-	0	Human	4.9	pIC50	=	4.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	10	4	5	3.0	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1C	nan
		CHEMBL3941270	148852	0	None	-	0	Human	4.9	pIC50	=	4.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	10	4	5	3.0	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1C	nan
		118334912	154322	0	None	-	0	Human	4.9	pIC50	=	4.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	572	11	4	7	1.8	CS(=O)(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		CHEMBL3986723	154322	0	None	-	0	Human	4.9	pIC50	=	4.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	572	11	4	7	1.8	CS(=O)(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		118334831	147116	0	None	-	0	Human	6.7	pIC50	=	6.7	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
		CHEMBL3927475	147116	0	None	-	0	Human	6.7	pIC50	=	6.7	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
		CHEMBL507480	214335	0	None	-	0	Human	7.6	pIC50	=	7.6	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
		90154832	153119	0	None	-	0	Human	5.6	pIC50	=	5.6	Binding	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
		CHEMBL3976408	153119	0	None	-	0	Human	5.6	pIC50	=	5.6	Binding	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
		118334842	153852	0	None	-	0	Human	5.6	pIC50	=	5.6	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	562	10	4	5	3.4	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(F)(F)F)cc1	nan
		CHEMBL3982797	153852	0	None	-	0	Human	5.6	pIC50	=	5.6	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	562	10	4	5	3.4	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(F)(F)F)cc1	nan
		CHEMBL440082	213860	0	None	-	0	Human	7.6	pIC50	=	7.6	Binding	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)O	10.1021/jm0609059
		118334830	154245	0	None	-	0	Human	6.6	pIC50	=	6.6	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	528	10	4	5	3.0	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
		CHEMBL3986225	154245	0	None	-	0	Human	6.6	pIC50	=	6.6	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	528	10	4	5	3.0	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
		118334834	152311	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	5	3.5	CC(C)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		CHEMBL3969613	152311	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	5	3.5	CC(C)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		127035881	136485	0	None	-	0	Human	7.4	pIC50	=	7.4	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
		CHEMBL3736134	136485	0	None	-	0	Human	7.4	pIC50	=	7.4	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
		127035881	136485	0	None	-	0	Human	7.4	pIC50	=	7.4	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
		CHEMBL3736134	136485	0	None	-	0	Human	7.4	pIC50	=	7.4	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
		90154607	153804	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCO2	nan
		CHEMBL3982346	153804	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCO2	nan
		118334924	147137	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	542	11	3	5	3.7	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
		CHEMBL3927669	147137	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	542	11	3	5	3.7	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
		118334910	144648	0	None	-	0	Human	4.4	pIC50	=	4.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	11	5	6	2.4	CC(O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		CHEMBL3908152	144648	0	None	-	0	Human	4.4	pIC50	=	4.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	11	5	6	2.4	CC(O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		118334914	151359	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	12	4	5	3.3	CCCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		CHEMBL3961248	151359	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	12	4	5	3.3	CCCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		118334919	153535	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	13	4	6	3.1	CCCOc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		CHEMBL3980013	153535	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	13	4	6	3.1	CCCOc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		73890939	152831	0	None	-	0	Human	6.4	pIC50	=	6.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	6	2.6	CC(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		CHEMBL3973956	152831	0	None	-	0	Human	6.4	pIC50	=	6.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	6	2.6	CC(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		118334917	151203	0	None	-	0	Human	4.3	pIC50	=	4.3	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	13	4	6	3.5	CCC(C)Oc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		CHEMBL3959870	151203	0	None	-	0	Human	4.3	pIC50	=	4.3	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	13	4	6	3.5	CCC(C)Oc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
		118334925	142389	0	None	-	0	Human	5.3	pIC50	=	5.3	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	550	12	3	6	3.2	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(C)=O)cc1	nan
		CHEMBL3889643	142389	0	None	-	0	Human	5.3	pIC50	=	5.3	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	550	12	3	6	3.2	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(C)=O)cc1	nan
		127034614	136503	0	None	-	0	Human	7.3	pIC50	=	7.3	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
		CHEMBL3736230	136503	0	None	-	0	Human	7.3	pIC50	=	7.3	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
		127034614	136503	0	None	-	0	Human	7.3	pIC50	=	7.3	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
		CHEMBL3736230	136503	0	None	-	0	Human	7.3	pIC50	=	7.3	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
		118334931	142442	0	None	-	0	Human	5.2	pIC50	=	5.2	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	11	3	7	2.8	CO[C@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
		CHEMBL3890096	142442	0	None	-	0	Human	5.2	pIC50	=	5.2	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	11	3	7	2.8	CO[C@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
		118334909	149412	0	None	-	0	Human	5.2	pIC50	=	5.2	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	512	10	4	5	2.5	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(F)cc1	nan
		CHEMBL3945729	149412	0	None	-	0	Human	5.2	pIC50	=	5.2	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	512	10	4	5	2.5	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(F)cc1	nan
		3842	2436	0	None	-	0	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		1155	3572	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		16129665	3572	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		3643	3572	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		CHEMBL1201488	3572	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		DB00021	3572	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		3293	468	0	None	-	0	Rat	5.0	pIC50	=	5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		3293	468	0	None	-	0	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		1155	3572	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		16129665	3572	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		3643	3572	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		CHEMBL1201488	3572	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		DB00021	3572	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		1152	3995	16	None	-5	4	Human	8.3	pIC50	=	8.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		16129679	3995	16	None	-5	4	Human	8.3	pIC50	=	8.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		53395115	3995	16	None	-5	4	Human	8.3	pIC50	=	8.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		91898389	3995	16	None	-5	4	Human	8.3	pIC50	=	8.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		CHEMBL1981592	3995	16	None	-5	4	Human	8.3	pIC50	=	8.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		1152	3995	16	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		16129679	3995	16	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		53395115	3995	16	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		91898389	3995	16	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		CHEMBL1981592	3995	16	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		129887154	583	0	None	-	1	Human	7.2	pIC50	=	7.2	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		155817438	583	0	None	-	1	Human	7.2	pIC50	=	7.2	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		16214732	583	0	None	-	1	Human	7.2	pIC50	=	7.2	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		2269	583	0	None	-	1	Human	7.2	pIC50	=	7.2	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		2281	583	0	None	-	1	Human	7.2	pIC50	=	7.2	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		16133238	2990	0	None	-	3	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		2257	2990	0	None	-	3	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		44134520	2990	0	None	-	3	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		131850923	3077	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
		155817437	3077	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
		16154651	3077	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
		2268	3077	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
		131850923	3077	0	None	-	0	Rat	5.7	pIC50	=	5.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
		155817437	3077	0	None	-	0	Rat	5.7	pIC50	=	5.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
		16154651	3077	0	None	-	0	Rat	5.7	pIC50	=	5.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
		2268	3077	0	None	-	0	Rat	5.7	pIC50	=	5.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
		2266	2894	0	None	-	0	Human	7.3	pIC50	=	7.3	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
		16133238	2990	0	None	-	3	Human	7.6	pIC50	=	7.6	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
		2257	2990	0	None	-	3	Human	7.6	pIC50	=	7.6	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
		44134520	2990	0	None	-	3	Human	7.6	pIC50	=	7.6	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
		1152	3995	16	None	-5	4	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
		16129679	3995	16	None	-5	4	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
		53395115	3995	16	None	-5	4	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
		91898389	3995	16	None	-5	4	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
		CHEMBL1981592	3995	16	None	-5	4	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
		2259	3346	0	None	-	0	Human	8.7	pIC50	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
		2259	3346	0	None	-	0	Human	8.7	pIC50	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
		2259	3346	0	None	-	0	Human	8.7	pIC50	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9145428
		1155	3572	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		16129665	3572	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		3643	3572	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		CHEMBL1201488	3572	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		DB00021	3572	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		1155	3572	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		16129665	3572	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		3643	3572	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		CHEMBL1201488	3572	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		DB00021	3572	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		131850923	3077	0	None	-	0	Human	5.7	pIC50	=	5.7	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
		155817437	3077	0	None	-	0	Human	5.7	pIC50	=	5.7	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
		16154651	3077	0	None	-	0	Human	5.7	pIC50	=	5.7	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
		2268	3077	0	None	-	0	Human	5.7	pIC50	=	5.7	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
		2273	3109	0	None	-	0	Human	7.5	pIC50	=	7.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		2273	3109	0	None	-	0	Rat	7.5	pIC50	=	7.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		16133238	2990	0	None	-	3	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		16133238	2990	0	None	-	3	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		2257	2990	0	None	-	3	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		2257	2990	0	None	-	3	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		44134520	2990	0	None	-	3	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		44134520	2990	0	None	-	3	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		2275	3113	0	None	-	0	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		1152	3995	16	None	-5	4	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		1152	3995	16	None	-	4	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		16129679	3995	16	None	-5	4	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		16129679	3995	16	None	-	4	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		53395115	3995	16	None	-5	4	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		53395115	3995	16	None	-	4	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		91898389	3995	16	None	-5	4	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		91898389	3995	16	None	-	4	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		CHEMBL1981592	3995	16	None	-5	4	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		CHEMBL1981592	3995	16	None	-	4	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		2275	3113	0	None	-	0	Rat	8.2	pIC50	=	8.2	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		1152	3995	16	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		16129679	3995	16	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		53395115	3995	16	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		91898389	3995	16	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		CHEMBL1981592	3995	16	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		16132369	1918	0	None	-	1	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		16132369	1918	0	None	-	1	Rat	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		2280	1918	0	None	-	1	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		2280	1918	0	None	-	1	Rat	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		53230038	1918	0	None	-	1	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		53230038	1918	0	None	-	1	Rat	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		2271	2895	0	None	-	0	Rat	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		1152	3995	16	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
		1152	3995	16	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		16129679	3995	16	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
		16129679	3995	16	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		53395115	3995	16	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
		53395115	3995	16	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		91898389	3995	16	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
		91898389	3995	16	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		CHEMBL1981592	3995	16	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
		CHEMBL1981592	3995	16	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
		2272	3078	0	None	-	0	Human	8.7	pIC50	=	8.7	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11068102
		2271	2895	0	None	-	0	Human	9.0	pIC50	=	9	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
		3842	2436	0	None	-	0	Human	4.5	pIC50	>	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
		3842	2436	0	None	-	0	Human	6.0	pIC50	>	6	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
		129887154	583	0	None	-	1	Human	9.2	pKd	=	9.2	Binding	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		155817438	583	0	None	-	1	Human	9.2	pKd	=	9.2	Binding	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		16214732	583	0	None	-	1	Human	9.2	pKd	=	9.2	Binding	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		2269	583	0	None	-	1	Human	9.2	pKd	=	9.2	Binding	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		2281	583	0	None	-	1	Human	9.2	pKd	=	9.2	Binding	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
		53314964	216321	0	125I-VIP	-1	3	Rat	9.4	pKi	=	9.4	Binding	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
		53314964	216321	0	125I-VIP	-5	3	Human	8.7	pKi	=	8.7	Binding	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
		53314964	216321	0	125I-VIP	-1	3	Rat	8.7	pKi	=	8.7	Binding	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
		53314964	216321	0	125I-VIP	-5	3	Human	8.3	pKi	=	8.3	Binding	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
		53314964	216321	0	125I-VIP	-5	3	Human	8.2	pKi	=	8.2	Binding	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
		1152	3995	16	None	-5	4	Human	7.8	pKi	=	7.8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
		16129679	3995	16	None	-5	4	Human	7.8	pKi	=	7.8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
		53395115	3995	16	None	-5	4	Human	7.8	pKi	=	7.8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
		91898389	3995	16	None	-5	4	Human	7.8	pKi	=	7.8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
		CHEMBL1981592	3995	16	None	-5	4	Human	7.8	pKi	=	7.8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
		2276	3345	0	None	316	2	Human	8.0	pKi	=	8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
		2278	328	0	None	-316	2	Human	5.6	pKi	=	5.6	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
		1152	3995	16	None	-5	4	Human	8.8	pKi	=	8.8	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
		16129679	3995	16	None	-5	4	Human	8.8	pKi	=	8.8	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
		53395115	3995	16	None	-5	4	Human	8.8	pKi	=	8.8	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
		91898389	3995	16	None	-5	4	Human	8.8	pKi	=	8.8	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
		CHEMBL1981592	3995	16	None	-5	4	Human	8.8	pKi	=	8.8	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
		1152	3995	16	None	-5	4	Human	8.7	pKi	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
		16129679	3995	16	None	-5	4	Human	8.7	pKi	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
		53395115	3995	16	None	-5	4	Human	8.7	pKi	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
		91898389	3995	16	None	-5	4	Human	8.7	pKi	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
		CHEMBL1981592	3995	16	None	-5	4	Human	8.7	pKi	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823

Join us

Cite us

Main reference

Ligand source activities (1 row/activity)